Skip to main content
Clinical Trials/NCT03499314
NCT03499314
Completed
Not Applicable

A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)

NYU Langone Health1 site in 1 country65 target enrollmentApril 15, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
NYU Langone Health
Enrollment
65
Locations
1
Primary Endpoint
Mean Preload Phase Duration (PLD)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is a randomized, double-blind pilot clinical trial to test a novel treatment approach to rehabilitate fine motor function in individuals living with progressive multiple sclerosis (MS) using anodal transcranial direct current stimulation (tDCS) to augment manual dexterity training. Treatment will be delivered to individuals at home using a state-of-the-art remotely supervised tele-rehabilitation protocol, a major advantage for patients with respect to ease of access, feasibility, reinforcement learning and minimal burden of in clinic study visit participation. Improvements in fine motor skill will be assessed at each remote session using a novel portable grip device that measures execution and adaptation or learning of fingertip forces during grasp, which is more sensitive than standard measures of hand function.

Registry
clinicaltrials.gov
Start Date
April 15, 2018
End Date
November 30, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Definite MS diagnosis, progressive subtype
  • 9HPT score between -1.0 and -4.0 standard deviations from age-based normative data
  • Score of \< 7.5 or less on the EDSS (with caregiver proxy required for those with scores of 6.5 or greater)\*
  • Ability to understand the informed consent process and provide consent to participate in the study

Exclusion Criteria

  • Primary neurologic, psychiatric or other medical disorder other than MS
  • Use of upper extremity Botox injection within 3 months
  • Current use of intrathecal Baclofen
  • History of seizure disorder
  • History of head trauma or medical device in head or neck
  • Clinically significant abnormality on EKG
  • Symbol Digit Modalities Test or SDMT score ≥3.0 SD from published norms
  • WRAT-4 reading level below average (\<85) (estimated general intellectual function)
  • Skin disorder/sensitive near stimulation locations

Outcomes

Primary Outcomes

Mean Preload Phase Duration (PLD)

Time Frame: baseline and 30 minutes for each of 20 sessions, values averaged across sessions

(PLD) is the duration of finger contact until the onset of positive load force. It assesses the time taken to stabilize grasp and is a robust measure of grasp execution.

Study Sites (1)

Loading locations...

Similar Trials